<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623424</url>
  </required_header>
  <id_info>
    <org_study_id>14270</org_study_id>
    <nct_id>NCT04623424</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiota in Stem Cell Transplant Transplant Admission</brief_title>
  <official_title>Intestinal Microbiota Alteration by Antibiotics Used During Stem Cell Transplant Admission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, the primary objective will be to investigate the association&#xD;
      between the use of antibiotics administered during the admission period of Stem cell&#xD;
      transplant (SCT) and the rate of overall change in microbiota composition across adjacent&#xD;
      samples in time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early preclinical studies suggested that intestinal microflora contribute to aGVHD and may be&#xD;
      relapse. There is increasing evidence that use of antibiotics may have a detrimental impact&#xD;
      on intestinal microbiota composition and, consequently, the outcome of SCT.However, effect on&#xD;
      different antibiotic prophylaxis regimens and broad-spectrum antibiotics used during&#xD;
      transplant and the intestinal microbiota composition and hence adverse outcomes are not&#xD;
      known. Stool samples will be collected from patients who are undergoing SCT at:&#xD;
&#xD;
        1. preconditioning&#xD;
&#xD;
        2. at day 0 (stem cell infusion)&#xD;
&#xD;
        3. once in the period of day + 7-10 post SCT&#xD;
&#xD;
        4. once first day or second day of BMT OPD clinic visit&#xD;
&#xD;
        5. once if they develop &gt;=grade I GVHD&#xD;
&#xD;
        6. once at time of recovery from GVHD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">November 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in microbiome</measure>
    <time_frame>Up to 6 months post stem cell transplant</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>intestinal microbiota</intervention_name>
    <description>Stoll samples will be tested for different bacteria</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        stem cell transplant patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-80 years&#xD;
&#xD;
          -  patients undergoing allogenic or autologous SCT for malignant hematological conditions&#xD;
             or bone marrow failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shatha farhan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shatha farhan, MD</last_name>
    <phone>313 916 5002</phone>
    <email>SFARHAN1@HFHS.ORG</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shatha farhan</last_name>
      <phone>313-916-5002</phone>
      <email>sfarhan1@hfhs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Shatha Farhan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

